NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free SLRX Stock Alerts $0.49 -0.01 (-2.02%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$0.47▼$0.5650-Day Range$0.45▼$0.6852-Week Range$0.43▼$2.68Volume105,630 shsAverage Volume306,562 shsMarket Capitalization$2.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Salarius Pharmaceuticals alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.Click here to sign up for our free report & newsletter About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesApril 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.March 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugFebruary 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | msn.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | finance.yahoo.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 9, 2024 | uk.investing.comSalarius Pharmaceuticals Inc (SLRX)January 16, 2024 | finance.yahoo.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 13, 2024 | wsj.comSquare Pharmaceuticals Ltd.January 3, 2024 | finance.yahoo.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNovember 10, 2023 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 8, 2023 | morningstar.comSalarius Pharmaceuticals Inc SLRXNovember 7, 2023 | finance.yahoo.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 9, 2023 | finance.yahoo.comSLRX Pursuing Strategic AlternativesJuly 11, 2023 | benzinga.comWatching Salarius Pharma; Zacks Small-Cap Research Sets $6.75 Price TargetJuly 11, 2023 | finance.yahoo.comSLRX Continues Cancer Fight with Phase I Trial ApprovalJuly 11, 2023 | marketwatch.comSalarius Pharmaceuticals Gets FDA Clearance for Lymphoma Drug ApplicationJuly 11, 2023 | finance.yahoo.comSalarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma PatientsSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/18/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees2Year Founded2011Profitability EPS (Most Recent Fiscal Year)($4.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-197.96% Return on Assets-135.23% Debt Debt-to-Equity RatioN/A Current Ratio5.02 Quick Ratio5.02 Sales & Book Value Annual Sales$1.84 million Price / Sales1.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.36Miscellaneous Outstanding Shares4,310,000Free Float4,077,000Market Cap$2.09 million OptionableNot Optionable Beta1.01 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $729.58kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Comp: $409.98kDr. Nadeem Q. Mirza M.D.M.P.H., Senior Vice President of Clinical DevelopmentDr. Daniela Y. SantiestebanDirector of Targeted Protein Degradation ProgramKey CompetitorsHistogenNASDAQ:HSTONotable LabsNASDAQ:NTBLCyclacel PharmaceuticalsNASDAQ:CYCCCNS PharmaceuticalsNASDAQ:CNSPClearmind MedicineNASDAQ:CMNDView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 137,000 shares on 2/13/2024Ownership: 2.234%View All Institutional Transactions SLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Salarius Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares. View SLRX analyst ratings or view top-rated stocks. How have SLRX shares performed in 2024? Salarius Pharmaceuticals' stock was trading at $0.65 at the beginning of the year. Since then, SLRX shares have decreased by 25.2% and is now trading at $0.4860. View the best growth stocks for 2024 here. Are investors shorting Salarius Pharmaceuticals? Salarius Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 268,900 shares, an increase of 1,767.4% from the March 15th total of 14,400 shares. Based on an average daily volume of 114,300 shares, the short-interest ratio is currently 2.4 days. Currently, 6.7% of the company's shares are short sold. View Salarius Pharmaceuticals' Short Interest. When is Salarius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SLRX earnings forecast. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its quarterly earnings data on Friday, March, 22nd. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.01) by $0.79. What ETF holds Salarius Pharmaceuticals' stock? Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.09% of its portfolio. When did Salarius Pharmaceuticals' stock split? Shares of Salarius Pharmaceuticals reverse split before market open on Monday, October 17th 2022. The 1-25 reverse split was announced on Monday, October 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRX) was last updated on 4/18/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profits[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressYour Money is Not SafeAmerican AlternativeUrgent alert: open this for a huge profit potentialTimothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.